Cited by 340Barrier Structure and Function StudiesDrug Transport and Resistance MechanismsAlzheimer's disease research and treatments

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy

Open access

Desai, Brinda S., Monahan, Angela J., Carvey, Paul M., Hendey, Bill·2007·Cell Transplantation

DOI 10.3727/000000007783464731

Open this paper in CoChat — free account

Abstract

The blood–brain barrier (BBB) is a tightly regulated barrier in the central nervous system. Though the BBB is thought to be intact during neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), recent evidence argues otherwise. Dysfunction of the BBB may be involved in disease progression, eliciting of peripheral immune response, and, most importantly, altered drug efficacy. In this review, we will give a brief overview of the BBB, its components, and their functions. We will critically evaluate the current literature in AD and PD BBB pathology resulting from insult, neuroinflammation, and neurodegeneration. Specifically, we will discuss alterations in tight junction, transport and endothelial cell surface proteins, and vascular density changes, all of which result in altered permeability. Finally, we will discuss the implications of BBB dysfunction in current and future therapeutics. Developing a better appreciation of BBB dysfunction in AD and PD may not only provide novel strategies in treatment, but will prove an interesting milestone in understanding neurodegenerative disease etiology and progression.

Integrity signals

Registry

Crossref · 10.3727/000000007783464731

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Alzheimer’s disease
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
J. Submicrosc. Cytol. Pathol.
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,366
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
Schinkel, A. H., Smit, J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., Riele, H. T., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,284
Size-selective loosening of the blood-brain barrier in claudin-5–deficient mice
Nitta, T., Hata, M., Gotoh, S., Seo, Y., Sasaki, H., Hashimoto, N., Furuse, M., & Tsukita, S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302070 · Cited by 1,917
Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287

Show all 117 references

Research works printed but not linked: 14

Bernheimer H., 1973, Clinical, morphological and neurochemical correlations. J. Neurol. Sci., 20, 415
Dahlstrom A., 1990, J. Neural Transm. Suppl., 29, 195
Desai B. S., 2006, Soc. Neurosci. Abstr.
Ehrlich P., 1904, Gesammelte Arbeiten zur Immunitaetsforschung, 574
Goldmann E., 1913, Abhandl Konigl preuss Akad Wiss, 1, 1
Iwasaki T., 1999, J. Med. Dent. Sci., 46, 31
Kalaria R. N., 1992, Cerebrovasc. Brain Metab. Rev., 4, 226
Kemper E. M., 2004, Rev., 30, 415
Larsen N., 2005, Soc. Neurosci. Abstr.
Parachikova A., 2006, Neurobiol. Aging
Sayre L. M., 2000, Cell. Mol. Biol. (Noisy-le-grand), 46, 731
Simpson I. A., 2002, Diabetes Nutr. Metab., 15, 281
Verbeek M. M., 1994, Am. J. Pathol., 144, 104
Zipser B. D., 2006, Neurobiol. Aging;

Sorted by citations

Items 101–200 of 340

Designing peptide nanoparticles for efficient brain delivery
Duro‐Castaño, A., Leite, D. M., Forth, J., Deng, Y., Matias, D., Noble-Jesus, C., & Battaglia, G. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.001 · Cited by 53
Role of proteoglycans in neuro-inflammation and central nervous system fibrosis
Heindryckx, F., & Li, J. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.015 · Cited by 50
Ultrasonic stimulation of the brain to enhance the release of dopamine – A potential novel treatment for Parkinson’s disease
Xu, T., Lu, X., Peng, D., Wang, G., Chen, C., Liu, W., Wu, W., & Mason, T. J. (2019) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2019.104955 · Cited by 51
RETRACTED: In Vitro Modeling of Blood-Brain Barrier with Human iPSC-Derived Endothelial Cells, Pericytes, Neurons, and Astrocytes via Notch Signaling
Yamamizu, K., Iwasaki, M., Takakubo, H., Sakamoto, T., Ikuno, T., Miyoshi, M., Kondo, T., Nakao, Y., Nakagawa, M., Inoue, H., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.01.023 · Cited by 51
Retracted
Progress in the Treatment of Central Nervous System Diseases Based on Nanosized Traditional Chinese Medicine
Li, J., Long, Q., Ding, H., Wang, Y., Luo, D., Li, Z., & Zhang, W. (2024) · Advanced Science · doi:10.1002/advs.202308677 · Cited by 47
Myeloid Dendritic Cells are Potential Players in Human Neurodegenerative Diseases
Bossù, P., Spalletta, G., Caltagirone, C., & Ciaramella, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00632 · Cited by 51
Alcohol, inflammation, and blood-brain barrier function in health and disease across development
Vore, A. S., & Deak, T. (2021) · International review of neurobiology · doi:10.1016/bs.irn.2021.06.009 · Cited by 53
Pulse Pressure: An Emerging Therapeutic Target for Dementia
Levin, R., Carnegie, M. H., & Celermajer, D. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00669 · Cited by 48
Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson’s disease mouse model
Mobahat, M., Sadroddiny, E., Nooshabadi, V. T., Ebrahimi‐Barough, S., Goodarzi, A., Malekshahi, Z. V., & Ai, J. (2022) · Cell and Tissue Banking · doi:10.1007/s10561-022-10008-6 · Cited by 46
Efflux proteins at the blood–brain barrier: review and bioinformatics analysis
Saidijam, M., Dermani, F. K., Sohrabi, S., & Patching, S. G. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1328148 · Cited by 48
Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases
Walker, D. G., Lue, L., Serrano, G. E., Adler, C. H., Caviness, J. N., Sue, L. I., & Beach, T. G. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00507 · Cited by 44
Paving the Way Toward Complex Blood-Brain Barrier Models Using Pluripotent Stem Cells
Lauschke, K., Frederiksen, L., & Hall, V. J. (2017) · Stem Cells and Development · doi:10.1089/scd.2017.0003 · Cited by 46
Detrimental Roles of Hypoxia-Inducible Factor-1α in Severe Hypoxic Brain Diseases
Choi, Y. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084465 · Cited by 45
Pathogenic role of ganglioside metabolism in neurodegenerative diseases
Ariga, T. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23411 · Cited by 43
Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of α-synuclein neuropathology required and feasible?
Vernon, A. C., Ballard, C. G., & Modo, M. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2010.05.006 · Cited by 44
Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis
Liu, Y., Wang, Y., Ye, Y.-C., Zhao, W., & Li, L. (2017) · Archives of Dermatological Research · doi:10.1007/s00403-017-1736-1 · Cited by 43
Brain Disorders and Chemical Pollutants: A Gap Junction Link?
Mesnil, M., Defamie, N., Naus, C. C. G., & Sarrouilhe, D. (2020) · Biomolecules · doi:10.3390/biom11010051 · Cited by 45
Identification of potential therapeutic compounds for Parkinson's disease using Drosophila and human cell models
Sanz, F., Solana‐Manrique, C., Muñoz, V. F. L., Calap-Quintana, P., Moltó, M. D., & Paricio, N. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.364 · Cited by 42
Age-related brain atrophy is not a homogenous process: Different functional brain networks associate differentially with aging and blood factors
Markov, N. T., Lindbergh, C. A., Staffaroni, A. M., Pérez, K., Stevens, M., Nguyen, K., Murad, N. F., Fonseca, C. S., Campisi, J., Kramer, J. H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2207181119 · Cited by 43
Blood–brain barrier impairment is functionally correlated with clinical severity in patients of multiple system atrophy
Song, S., Lee, S., Lee, J. J., Lee, J. E., Choi, H. S., Sohn, Y. H., & Lee, P. H. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.12.017 · Cited by 41
Pathophysiological Role of Microglial Activation Induced by Blood-Borne Proteins in Alzheimer’s Disease
Kim, S., Sharma, C., Jung, U. J., & Kim, S. R. (2023) · Biomedicines · doi:10.3390/biomedicines11051383 · Cited by 40
Human Bone Marrow Endothelial Progenitor Cell Transplantation into Symptomatic ALS Mice Delays Disease Progression and Increases Motor Neuron Survival by Repairing Blood-Spinal Cord Barrier
Garbuzova-Davis, S. N., Kurien, C., Haller, E. M., Eve, D. J., Navarro, S., Steiner, G. A., Mahendrasah, A., Hailu, S., Khatib, M., Boccio, K. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41747-4 · Cited by 40
Claudin-5 and occludin levels in patients with psychiatric disorders − A systematic review
Maridaki, Z., Syrros, G., Delichatsiou, S. G., Warsh, J. J., & Konstantinou, G. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.11.006 · Cited by 39
The mechanisms of perineuronal net abnormalities in contributing aging and neurological diseases
Dong, Y., Zhao, K., Qin, X., Du, G., & Gao, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102092 · Cited by 39
Distribution of human umbilical cord blood-derived mesenchymal stem cells in the Alzheimer’s disease transgenic mouse after a single intravenous injection
Park, S. E., Lee, N. K., Lee, J., Hwang, J. W., Choi, S. J., Hwang, H., Hyung, B., Chang, J. W., & Na, D. L. (2016) · Neuroreport · doi:10.1097/wnr.0000000000000526 · Cited by 38
Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson’s disease mouse model: Endothelial and microglial effects
Burks, S. M., Raymick, J. B., Robinson, B. L., Hanig, J. P., & Sarkar, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.03.015 · Cited by 38
Microphysiological Blood‐Brain Barrier Systems for Disease Modeling and Drug Development
Mulay, A. R., Hwang, J., & Kim, D. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303180 · Cited by 37
Modeling Alzheimer’s disease with human iPS cells: advancements, lessons, and applications
Essayan-Perez, S., Zhou, B., Nabet, A. M., Wernig, M., & Huang, Y. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104503 · Cited by 40
Proteins and Transcriptional Dysregulation of the Brain Extracellular Matrix in Parkinson’s Disease: A Systematic Review
Rike, W. A., & Stern, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087435 · Cited by 43
Estimating Blood and Brain Concentrations and Blood-to-Brain Influx by Magnetic Resonance Imaging with Step-Down Infusion of Gd-DTPA in Focal Transient Cerebral Ischemia and Confirmation by Quantitative Autoradiography with Gd-[ 14 C]DTPA
Knight, R. A., Karki, K., Ewing, J. R., Divine, G., Fenstermacher, J. D., Patlak, C. S., & Nagaraja, T. N. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.20 · Cited by 37
Cytokine signaling in the human brain capillary endothelial cell line hCMEC/D3
Fasler‐Kan, E., Suenderhauf, C., Barteneva, N. S., Poller, B., Gygax, D., & Huwyler, J. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.077 · Cited by 40
Blood-brain Barrier and Neurovascular Unit Dysfunction in Parkinson's Disease: From Clinical Insights to Pathogenic Mechanisms and Novel Therapeutic Approaches
Khor, S. L. Q., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230330093829 · Cited by 37
Role of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier
Cazalla, E., Cuadrado, A., & García‐Yagüe, Á. J. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00599-5 · Cited by 36
Non-Coding RNAs in the Brain-Heart Axis: The Case of Parkinson’s Disease
Acharya, S., Salgado‐Somoza, A., Stefanizzi, F. M., Lumley, A. I., Zhang, L., Glaab, E., May, P., & Devaux, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186513 · Cited by 33
A deep learning approach to predict blood-brain barrier permeability
Alsenan, S. A., Al-Turaiki, I. M., & Hafez, A. M. (2021) · PeerJ Computer Science · doi:10.7717/peerj-cs.515 · Cited by 36
Targeted Discovery and Validation of Plasma Biomarkers of Parkinson’s Disease
Pan, C., Zhou, Y. F., Dator, R., Ginghină, C., Zhao, Y., Movius, J., Peskind, E. R., Zabetian, C. P., Quinn, J. F., Galasko, D., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr500421v · Cited by 34
Immunology meets neuroscience – Opportunities for immune intervention in neurodegenerative diseases
Lynch, M. A., & Mills, K. H. G. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.05.013 · Cited by 34
Development of biocompatible nanogel for sustained drug release by overcoming the blood brain barrier in zebrafish model
Sivaji, K., Pitchai, A., Soundharapandiyan, N., Joseph, B., Iniyan, A. M., Vincent, S. G. P., & Kannan, R. R. (2016) · Journal of Applied Biomedicine · doi:10.1016/j.jab.2016.01.004 · Cited by 33
KDM4B histone demethylase and G9a regulate expression of vascular adhesion proteins in cerebral microvessels
Choi, J.-Y., Yoon, S. S., Kim, S.-E., & Jo, S. A. (2017) · Scientific Reports · doi:10.1038/srep45005 · Cited by 33
A Single Domain Shark Antibody Targeting the Transferrin Receptor 1 Delivers a TrkB Agonist Antibody to the Brain and Provides Full Neuroprotection in a Mouse Model of Parkinson’s Disease
Clarke, E., Stocki, P., Sinclair, E. H., Gauhar, A., Fletcher, E. J. R., Krawczun-Rygmaczewska, A., Duty, S., Walsh, F. S., Doherty, P., & Rutkowski, J. L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071335 · Cited by 32
T-Lymphocyte Deficiency Exacerbates Behavioral Deficits in the 6-OHDA Unilateral Lesion Rat Model for Parkinson’s Disease
Wheeler, C. J. (2014) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.1000209 · Cited by 32
Cerebrospinal Fluid C-Reactive Protein in Parkinson’s Disease: Associations with Motor and Non-motor Symptoms
Moghaddam, H. S., valitabar, Z., Ashraf‐Ganjouei, A., Zadeh, M. M., Sherbaf, F. G., & Aarabi, M. H. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-018-8499-5 · Cited by 32
Condition-specific gene co-expression network mining identifies key pathways and regulators in the brain tissue of Alzheimer’s disease patients
Xiang, S., Huang, Z., Wang, T., Han, Z., Yu, C. Y., Ni, D., Huang, K., & Zhang, J. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0431-1 · Cited by 32
Stem Cell Therapy for Neurodegenerative Diseases: How Do Stem Cells Bypass the Blood-Brain Barrier and Home to the Brain?
Chia, Y. C., Anjum, C. E., Yee, H. R., Kenisi, Y., Chan, M. K., Wong, M. B., & Pan, S. Y. (2020) · Stem Cells International · doi:10.1155/2020/8889061 · Cited by 34
REMOVED: Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease
Ozkızılcık, A., Sharma, A., Lafuente, J. V., Muresanu, D. F., Nozari, A., Tian, Z. R., Mössler, H., & Sharma, H. S. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.014 · Cited by 29
Using multi-organ culture systems to study Parkinson’s disease
Reiner, O., Sapir, T., & Parichha, A. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00936-8 · Cited by 32
Pathological and biochemical alterations of astrocytes in ovariectomized rats injected with d-galactose: A potential contribution to Alzheimer's disease processes
Hua, X., Lei, M., Ding, J., Qun-ying, H., Hu, G., & Xiao, M. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.01.009 · Cited by 29
Adolescent intermittent ethanol exposure produces Sex-Specific changes in BBB Permeability: A potential role for VEGFA
Vore, A. S., Barney, T. M., Deak, M. M., Varlinskaya, E. I., & Deak, T. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.02.030 · Cited by 29
Disruption of neuronal-glial-vascular units in the hippocampus of ovariectomized mice injected with d-galactose
Liu, L., Su, Y., Yang, W., Xiao, M., Gao, J., & Hu, G. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.028 · Cited by 28
Biological activities of the LXRα and β agonist, 4β-hydroxycholesterol, and of its isomer, 4α-hydroxycholesterol, on oligodendrocytes: Effects on cell growth and viability, oxidative and inflammatory status
Nury, T., Samadi, M. H., Varin, A., Lopez, T. E., Zarrouk, A., Boumhras, M., Riedinger, J., Masson, D., Véjux, A., & Lizard, G. (2012) · Biochimie · doi:10.1016/j.biochi.2012.11.013 · Cited by 28
Survival of transplanted human neural stem cell line (ReNcell VM) into the rat brain with and without immunosuppression
Hovakimyan, M., Müller, J. A., Wree, A., Ortinau, S., Rolfs, A., & Schmitt, O. (2012) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2012.05.003 · Cited by 27
Role of ginseng in the neurovascular unit of neuroinflammatory diseases focused on the blood-brain barrier
Kim, M., Mok, H., Yeo, W., Ahn, J., & Choi, Y. K. (2021) · Journal of Ginseng Research · doi:10.1016/j.jgr.2021.02.003 · Cited by 28
Pathways towards an effective immunotherapy for Parkinson’s disease
Hutter-Saunders, J. A. L., Mosley, R. L., & Gendelman, H. E. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.163 · Cited by 28
Improved Method for the Establishment of an In Vitro Blood-Brain Barrier Model Based on Porcine Brain Endothelial Cells
Nielsen, S. S. E., Siupka, P., Georgian, A. R., Preston, J. E., Tóth, A. E., Yusof, S. R., Abbott, N. J., & Nielsen, M. S. (2017) · Journal of Visualized Experiments · doi:10.3791/56277 · Cited by 33
Intravenous ascorbate improves spatial memory in middle-aged APP/PSEN1 and wild type mice
Kennard, J. A., & Harrison, F. E. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.01.044 · Cited by 26
Modification of Glial Cell Activation through Dendritic Cell Vaccination: Promises for Treatment of Neurodegenerative Diseases
Sabahi, M., Joshaghanian, A., Dolatshahi, M., Jabbari, P., Rahmani, F., & Rezaei, N. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01818-6 · Cited by 26
Decoding Common Features of Neurodegenerative Disorders: From Differentially Expressed Genes to Pathways
Habib, R., Noureen, N., & Nadeem, N. (2018) · Current Genomics · doi:10.2174/1389202918666171005100549 · Cited by 26
Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson’s disease
Ng, A. S. L., Tan, Y. J., Lu, Z., Ng, E. Y., Ng, S. Y., Chia, N. S. Y., Setiawan, F., Xu, Z., Keong, N. C. H., Tay, K. Y., et al. (2020) · Aging · doi:10.18632/aging.102695 · Cited by 26
Novel therapeutic opportunities for neurodegenerative diseases with mesenchymal stem cells: the focus on modulating the blood-brain barrier
Vargas-Rodríguez, P., Cuenca-Martagón, A., Castillo-González, J., Serrano-Martínez, I., Luque, R. M., Delgado, M., & González-Rey, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814117 · Cited by 25
Insights into the role of neutrophils in neuropsychiatric systemic lupus erythematosus: Current understanding and future directions
Sim, T. M., Mak, A., & Tay, S. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.957303 · Cited by 24
Characterization of changes in global gene expression in the brain of neuron-specific enolase/human Tau23 transgenic mice in response to overexpression of Tau protein
Hwang (2010) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000390 · Cited by 25
Involvement of Testosterone Signaling in the Integrity of the Neurovascular Unit in the Male: Review of Evidence, Contradictions, and Hypothesis
Ahmadpour, D., & Grange‐Messent, V. (2020) · Neuroendocrinology · doi:10.1159/000509218 · Cited by 22
Three-Dimensional in vitro Models of Healthy and Tumor Brain Microvasculature for Drug and Toxicity Screening
Piantino, M., Figarol, A., & Matsusaki, M. (2021) · Frontiers in Toxicology · doi:10.3389/ftox.2021.656254 · Cited by 25
Modeling the blood-brain barrier for treatment of central nervous system (CNS) diseases
Rice, O., Surian, A., & Chen, Y. (2022) · Journal of Tissue Engineering · doi:10.1177/20417314221095997 · Cited by 25
Nanomedicine Faces Barriers
Debbage, P. L., & Thurner, G. C. (2010) · Pharmaceuticals · doi:10.3390/ph3113371 · Cited by 23
Brain Targeting Nanomedicines: Pitfalls and Promise
Käkinen, A., Jiang, Y., Davis, T. P., Teesalu, T., & Saarma, M. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s454553 · Cited by 26
Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson’s Disease
Wu, Z., Wu, S., Liang, T., & Wang, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.633022 · Cited by 23
The emerging role of the microbiome in Alzheimer's disease
Wasén, C., Simonsen, E., Ekwudo, M. N., Profant, M. R., & Cox, L. M. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.09.001 · Cited by 24
Functional and Molecular Characterization of the Effect of Amyloid-β 42 on an in vitro Epithelial Barrier Model
Gheorghiu, M., Enciu, A., Popescu, B. O., & Gheorghiu, E. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122374 · Cited by 22
Induction of Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 via CD47 Signaling in Neurovascular Cells
Xing, C., Arai, K., Park, K., & Lo, E. H. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0159-6 · Cited by 22
An Investigation for Large Volume, Focal Blood-Brain Barrier Disruption with High-Frequency Pulsed Electric Fields
Lorenzo, M. F., Campelo, S. N., Arroyo, J. P., Aycock, K. N., Hinckley, J., Arena, C. B., Rossmeisl, J. H., & Davalos, R. V. (2021) · Pharmaceuticals · doi:10.3390/ph14121333 · Cited by 21
Senescence in brain pericytes attenuates blood-brain barrier function in vitro: A comparison of serially passaged and isolated pericytes from aged rat brains
Iwao, T., Takata, F., Matsumoto, J., Goto, Y., Aridome, H., Yasunaga, M., Yokoya, M., Kataoka, Y., & Dohgu, S. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.01.037 · Cited by 21
Lutein and the Underlying Neuroprotective Promise against Neurodegenerative Diseases
Iyer, S., Bhat, I., & Sheshappa, M. B. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300409 · Cited by 22
Effects of CBV, CBF, and blood-brain barrier permeability on accuracy of PASL and VASO measurement
Wu, C. W., Liu, H., Chen, J., & Yang, Y. (2010) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22165 · Cited by 21
Emerging contributions of formyl peptide receptors to neurodegenerative diseases
Busch, L., Vieten, S., Brödel, S., Endres, K., & Bufe, B. (2021) · Biological Chemistry · doi:10.1515/hsz-2021-0258 · Cited by 21
An Effective Method to Identify Shared Pathways and Common Factors among Neurodegenerative Diseases
Li, P., Nie, Y., & Yu, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143045 · Cited by 22
Adult neurogenesis pharmacology in neurological diseases and disorders
Taupin, P. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.2.311 · Cited by 21
The role of reactive oxygen species in the regulation of the blood-brain barrier
Shuvalova, M. L., Dmitrieva, A., Belousov, V. V., & Nosov, G. (2024) · Tissue Barriers · doi:10.1080/21688370.2024.2361202 · Cited by 21
Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson’s Disease
Huang, R., Gao, Y., Duan, Q., Zhang, Q., He, P., Chen, J., Ma, G., Wang, L., Zhang, Y., Nie, K., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03119-4 · Cited by 20
Modular tissue-in-a-CUBE platform to model blood-brain barrier (BBB) and brain interaction
Koh, I., & Hagiwara, M. (2024) · Communications Biology · doi:10.1038/s42003-024-05857-8 · Cited by 22
Small Particles, Big Potential: Polymeric Nanoparticles for Drug Delivery in Parkinson's Disease
Virameteekul, S., Lees, A. J., & Bhidayasiri, R. (2024) · Movement Disorders · doi:10.1002/mds.29939 · Cited by 23
In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer’s disease
Hu, X., Dong, W., Cui, Z.-W., Gao, C., Yu, Z., Yuan, Q., & Min, Z.-L. (2018) · Journal of Molecular Modeling · doi:10.1007/s00894-018-3696-6 · Cited by 20
Roles of Non-Coding RNAs as Novel Diagnostic Biomarkers in Parkinson’s Disease
Manna, I., Quattrone, A., Benedittis, S. D., Iaccino, E., & Quattrone, A. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212726 · Cited by 19
A Hybrid Nanofiber/Paper Cell Culture Platform for Building a 3D Blood–Brain Barrier Model
Huang, K., Castiaux, A. D., Podicheti, R., Rusch, D. B., Martin, R. S., & Baker, L. A. (2021) · Small Methods · doi:10.1002/smtd.202100592 · Cited by 19
The Potential of Pathological Protein Fragmentation in Blood-Based Biomarker Development for Dementia – With Emphasis on Alzheimer’s Disease
Inekci, D., Jonesco, D. S., Kennard, S., Karsdal, M. A., & Henriksen, K. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00090 · Cited by 19
Alzheimer Disease and Cellular Mechanisms of Memory Storage
Arshavsky, Y. I. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000043 · Cited by 19
The emerging field of cell and tissue engineering.
Park, D., Borlongan, C. V., Eve, D. J., & Sanberg, P. R. (2008) · PubMed · Cited by 19
Inhibition of peripheral VEGF signaling rapidly reduces leucocyte obstructions in brain capillaries and increases cortical blood flow in an Alzheimer’s disease mouse modelPreprint
Ali, M. A., Falkenhain, K., Njiru, B. N., Murtaza-Ali, M., Ruiz‐Uribe, N. E., Haft‐Javaherian, M., Catchers, S., Nishimura, N., Schaffer, C. B., & Bracko, O. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.05.433976 · Cited by 19
A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models
Kumar, V., Lee, J. D., Coulson, E. J., & Woodruff, T. M. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15119 · Cited by 18
The pleiotropic effects of antithrombotic drugs in the metabolic–cardiovascular–neurodegenerative disease continuum: impact beyond reduced clotting
Alaaeddine, R. A., AlZaim, I., Hammoud, S. H., Arakji, A., Eid, A. H., Abd‐Elrahman, K. S., & EL‐Yazbi, A. F. (2021) · Clinical Science · doi:10.1042/cs20201445 · Cited by 18
Inhibition of vascular adhesion protein 1 protects dopamine neurons from the effects of acute inflammation and restores habit learning in the striatum
Becchi, S., Buson, A., & Balleine, B. W. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02288-8 · Cited by 17
Comparative study between bone marrow mesenchymal stem cell and their conditioned medium in the treatment of rat model of Parkinsonism
Abdelwahab, S. A., Elsebay, S. A. G., Ibrahim, M. F. G., & Hafez, S. M. N. A. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29872 · Cited by 18
A gain-of-function screen in zebrafish identifies a guanylate cyclase with a role in neuronal degeneration
Maddison, L. A., Lu, J., Victoroff, T. M., Scott, E. K., Baier, H., & Chen, W. (2009) · Molecular Genetics and Genomics · doi:10.1007/s00438-009-0428-8 · Cited by 18
Understanding Human Cerebral Malaria through a Blood Transcriptomic Signature: Evidences for Erythrocyte Alteration, Immune/Inflammatory Dysregulation, and Brain Dysfunction
Cabantous, S., Poudiougou, B., Bergon, A., Barry, A., Oumar, A. A., Traore, A. M., Chevillard, C., Doumbo, O. K., Dessein, A. J. J., & Marquet, S. (2020) · Mediators of Inflammation · doi:10.1155/2020/3280689 · Cited by 17
Parkinson Disease ‐Targeted Nanocapsules for Synergistic Treatment: Combining Dopamine Replacement and Neuroinflammation Mitigation
Liu, Z., Xiang, S., Chen, B., Li, J., Zhu, D., Xu, H., & Hu, S. (2024) · Advanced Science · doi:10.1002/advs.202404717 · Cited by 19
HIV-associated neurocognitive disorders (HAND): Optimal diagnosis, antiviral therapy, pharmacological treatment, management, and future scopes
Adhikary, K., Banerjee, A., Sarkar, R., Banerjee, R., Chowdhury, S. R., Ganguly, K., & Karak, P. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123410 · Cited by 21
Reduction of glutamate-induced excitotoxicity in murine primary neurons involving calpain inhibition
Gold, M., Koczulla, A. R., Mengel, D., Koepke, J., Dodel, R. C., Dontcheva, G., Habib, P., & Bach, J. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.11.016 · Cited by 16
A potent and selective inhibitor for the modulation of MAGL activity in the neurovasculature
Kemble, A. M., Hornsperger, B., Ruf, I., Richter, H. G., Benz, J., Kuhn, B., Heer, D., Wittwer, M., Engelhardt, B., Grether, U., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268590 · Cited by 15
Differential responses of primary neuron-secreted MCP-1 and IL-9 to type 2 diabetes and Alzheimer’s disease-associated metabolites
Ball, B. K., Kuhn, M. K., Fleeman, R. M., Proctor, E. A., & Brubaker, D. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-62155-3 · Cited by 16
La maladie d’Alzheimer : des lésions cérébrales aux perspectives thérapeutiques
Forette, F., & Forette, F. (2008) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32836-5 · Cited by 15

Authors: Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B.
Affiliations: Department of Pharmacology, Rush University Medical Center, Chicago IL, USA
Rush University Medical Center (US)
Venue: Cell Transplantation
Publisher: SAGE Publications
Published: 2007-03
Volume: 16
Issue: 3
Pages: 285-299
ISSN: 0963-6897 (ISSN-L)
1555-3892
DOI: 10.3727/000000007783464731
OpenAlex: W2316522881
Cited by: 339
References: 117
Citations by year: 2026: 13 · 2025: 14 · 2024: 28 · 2023: 31 · 2022: 23 · 2021: 33 · 2020: 37 · 2019: 13 · 2018: 15 · 2017: 16 · 2016: 11 · 2015: 12 · 2014: 12 · 2013: 18 · 2012: 8
FWCI: 1.29
Type: journal article
Language: en
Open access: green
doaj.org
Licence: cc-by-sa
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Cell Transplantation (publishedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Institutes of Health (5r01ns045316-03, W81XWH-04-01-0365)
U.S. Public Health Service (012307)
National Institute of Allergy and Infectious Diseases (R01AI051619, R01AI51619)
National Institute of Neurological Disorders and Stroke (NS045316)
Topics: Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: blood-brain barrier, Alzheimer's disease, Parkinson's disease, BBB dysfunction, tight junctions, blood-brain barrier permeability, neuroinflammation, neurodegeneration, brain drug delivery, vessel density, neurodegenerative disease therapeutics
MeSH terms: Alzheimer Disease, Biological Transport, Blood-Brain Barrier, Humans, Parkinson Disease, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks